Physician profile

Jay Lee

Cardiovascular Disease · Orange, CA

NPI 1053346858

$35,169.04

in general payments reported to CMS, 2019-2025

38 companies · $1,296 in 2025

The $1,296 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$6,461.16
Food and Beverage$3,896.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $17,650.98 2019-2024 Xarelto
Boston Scientific Corporation $4,440.90 2019-2025 General - Therapies, Rhythmia Mapping System, General - Ep
Abbott Laboratories $3,851.41 2019-2025 Aveir, Agilis
Regeneron Pharmaceuticals, INC. $3,511.72 2024 Libtayo
Biosense Webster, INC. $809.66 2019-2024 Carto 3
Novartis Pharmaceuticals Corporation $661.99 2019-2025
Sanofi-Aventis U.S. LLC $578.90 2019-2024
Atricure, INC. $396.93 2019-2023
Pfizer INC. $332.77 2019-2025
Edwards Lifesciences Corporation $306.70 2023-2024 Pascal, Evoque
Medtronic, INC. $299.18 2022-2024 Selectsecure, Micra, Na
Astellas Pharma US INC $290.55 2021-2022
Cardiva Medical, INC. $271.06 2020-2025 Cardiva Vascade Mvp Vvcs 6-12f, Savvywire, Cardiva Vascade Mvp Xl Vvcs 10-12f
Kestra Medical Technology Services, INC. $243.78 2022-2025 Assure Wcd
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $225.67 2019-2025 Lifevest
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Abiomed $143.05 2019-2025
Penumbra, INC. $141.00 2021
Amgen INC. $114.86 2019-2023 Repatha
Acutus Medical, INC. $109.79 2022
Biotronik INC. $108.42 2025 Pantera Leo, Nhancer Rx, Recross
Boehringer Ingelheim Pharmaceuticals, INC. $107.00 2021-2024 Jardiance
E.R. Squibb & Sons, L.L.C. $63.57 2025 Camzyos
Cvrx, INC. $60.01 2022-2023 Barostim Neo System
Cardiovascular Systems INC. $56.64 2019-2021
Bardy Diagnostics, INC. $50.42 2019-2020
Astrazeneca Pharmaceuticals Lp $50.22 2019-2023 Farxiga
Philips North America LLC $40.17 2022
Merck Sharp & Dohme LLC $33.69 2024-2025 Verquvo
Scpharmaceuticals INC. $32.93 2024-2025
Ethicon US, LLC $28.48 2025 Vistaseal
Inari Medical, INC. $27.70 2021
Portola Pharmaceuticals, LLC $26.69 2019
Siemens Medical Solutions USA, INC. $20.09 2022
Altathera Pharmaceuticals LLC $19.95 2025 Sotalol Hydrochloride
Novo Nordisk INC $17.61 2024 Ozempic
Medtronic Vascular, INC. $17.16 2019
Amarin Pharma, INC. $14.46 2020
Kowa Pharmaceuticals America, INC. $12.93 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jay Lee

$35,169.04

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $1,296 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/229417/jay-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.